MedTrace Logo

Stem Cell Therapy for Amyotrophic Lateral Sclerosis

NCT01984814 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-10-25

No results posted yet for this study

Summary

The effect of autologous bone marrow mononuclear cells on duration of survival in Amyotrophic Lateral Sclerosis patients.

Conditions

Interventions

BIOLOGICAL

Stem cell

Autologous bone marrow derived mononuclear cells were administered via intrathecal and intramuscular routes.

Sponsors & Collaborators

  • Neurogen Brain and Spine Institute

    lead OTHER

Principal Investigators

  • Alok K Sharma, MS,MCh · Neurogen Brain and Spine Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
26 Years
Max Age
76 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01984814 on ClinicalTrials.gov